Twist Bioscience company profile
Company profile
Twist Bioscience has 979 employees and is headquartered in South San Francisco, United States.
Pharmaceutical and biotech companies, academic laboratories, diagnostics developers, and agricultural and industrial chemical firms are the main customers of this synthetic DNA producer. Its offering includes synthetic genes and gene fragments, oligo pools, antibody libraries, next-generation sequencing library preparation kits and target panels, as well as synthetic viral controls and research panels for respiratory viruses, including SARS-CoV-2. Revenue by region in the fiscal year ended September 2025 was 59.9% from the Americas, 33.0% from EMEA and 7.1% from Asia Pacific.
In the fiscal year ended September 30, 2025, revenue reached 376.6 million US dollars, up 20.3% from the previous year, while the company posted a net loss of 77.7 million US dollars. The company was founded in 2013 and employs 979 people. Its headquarters are in South San Francisco, California, United States.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 681 Gateway Boulevard, 94080, South San Francisco
- Employees
- 979
- Chief executive
- Emily Leproust
- Founded
- 2013
- Fiscal year
- October - September
- Listing
- TWST · NASDAQ
- Currency
- USD
- ISIN
- US90184D1000
- Website
- twistbioscience.com
Twist Bioscience and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Twist BioscienceTWST | United States | $7.4B | 979 | -28.8% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| ImmunityBioIBRX | United States | $6.4B | 684 | -150.2% | — |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
